Cobenfy as an adjunctive treatment to atypical antipsychotics did not reach the threshold for a statistically significant difference compared to placebo with an atypical antipsychotic for the primary endpoint of the change from baseline to Week 6 in the Positive and Negative Syndrome Scale (PANSS) total score
5 Likes
6 Likes
It did succeed at making me vomit.
3 Likes
From all that I’m seeing, it seems that Cobenfy is most effective as a standalone antipsychotic.
2 Likes
Here are the reviews of Cobenfy. There are only three. But more will be added over time. We should keep an eye out for new testimonials. My impression is that, in general, Cobenfy is better as monotherapy than current antipsychotics, primarily because it doesn’t cause weight gain. And also because in some cases it improves negative symptoms. But this last point doesn’t happen in everyone.
3 Likes
I guess I missed that… 
1 Like
so cobenfy isnt effective antipsychotic? Then why it get approved?
2 Likes
@Nirvana I don’t really understand: Is Cobenfy an adjunct or an antipsychotic? If it’s an antipsychotic that reduces negative symptoms in some people, I think it’s worth trying.
1 Like
@MIDO And how many hopes we had for Cobenfy!
It’s an antipsychotic, taken alone, as monotherapy. It’s better for negative symptoms than conventional antipsychotics. But the response is very heterogeneous. Some people don’t improve their negative symptoms at all.
1 Like
I’m scared to take cobenfy.
@Nirvana Thanks for your clarifying answer.
This is a money game. If Bristol Myers Squibb would lower the price, there would be many more consumers of Cobenfy and we would all understand what its effects are. I am from Eastern Europe, because of the unclear results and the high price, Cobenfy will have a hard time getting here.
1 Like